Literature DB >> 19857450

The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs.

David I Bernstein1, Nicholas Farley, Fernando J Bravo, Julie Earwood, Monica McNeal, Jeff Fairman, Rhonda Cardin.   

Abstract

Herpes simplex virus (HSV) infections are common but there is no vaccine available. We evaluated cationic liposome-DNA complexes (CLDC) as an adjuvant for an HSV gD2 vaccine and compared it to an MPL/Alum adjuvant in a guinea pig model of genital herpes. The addition of CLDC to the gD2 vaccine significantly decreased acute and recurrent disease and most importantly the number of days with recurrent virus shedding compared to gD2 alone. Reductions in these outcomes were also detected when gD2+CLDC was compared to gD2+MPL/Alum. When the vaccine and adjuvants were evaluated as therapeutic vaccines, they were ineffective. CLDC enhanced protection compared to MPL/Alum and is the first vaccine to reduce recurrent virus shedding, a key to decreasing the spread of HSV-2.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19857450      PMCID： PMC2862079          DOI： 10.1016/j.vaccine.2009.10.025

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  24 in total

1.  Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes.

Authors:  Karen Zaks; Michael Jordan; Amanda Guth; Karen Sellins; Ross Kedl; Angelo Izzo; Catharine Bosio; Steven Dow
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

2.  Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission.

Authors:  Gregory J Mertz
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

3.  Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.

Authors:  Nigel Bourne; Gregg N Milligan; Lawrence R Stanberry; Rachael Stegall; Richard B Pyles
Journal:  J Infect Dis       Date:  2005-11-11       Impact factor: 5.226

4.  Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.

Authors:  L Corey; A G Langenberg; R Ashley; R E Sekulovich; A E Izu; J M Douglas; H H Handsfield; T Warren; L Marr; S Tyring; R DiCarlo; A A Adimora; P Leone; C L Dekker; R L Burke; W P Leong; S E Straus
Journal:  JAMA       Date:  1999-07-28       Impact factor: 56.272

5.  Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously.

Authors:  S W Dow; L G Fradkin; D H Liggitt; A P Willson; T D Heath; T A Potter
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

Review 6.  Herpes simplex virus type 2: epidemiology and management options in developing countries.

Authors:  G Paz-Bailey; M Ramaswamy; S J Hawkes; A M Geretti
Journal:  Sex Transm Infect       Date:  2006-11-10       Impact factor: 3.519

Review 7.  Genital herpes.

Authors:  Rachna Gupta; Terri Warren; Anna Wald
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

8.  Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines.

Authors:  David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Jane E Strasser; Nicholas Farley; Claudia Chalk; Marla Lay; Jeff Fairman
Journal:  Clin Vaccine Immunol       Date:  2009-03-11

9.  Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study.

Authors:  Jeff Fairman; Joseph Moore; Mathieu Lemieux; Koen Van Rompay; Yongzhi Geng; John Warner; Kristina Abel
Journal:  Hum Vaccin       Date:  2009-03-14

10.  Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection.

Authors:  Marla Lay; Bernadette Callejo; Stella Chang; David K Hong; David B Lewis; Timothy D Carroll; Shannon Matzinger; Linda Fritts; Christopher J Miller; John F Warner; Lily Liang; Jeffery Fairman
Journal:  Vaccine       Date:  2009-05-09       Impact factor: 3.641
View more
  22 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

2.  Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.

Authors:  Christopher S Morello; Michael S Levinson; Kimberly A Kraynyak; Deborah H Spector
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig.

Authors:  David I Bernstein; Julie D Earwood; Fernando J Bravo; Gary H Cohen; Roselyn J Eisenberg; Jennifer R Clark; Jeffrey Fairman; Rhonda D Cardin
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

4.  Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity.

Authors:  Angela Henderson; Katie Propst; Ross Kedl; Steven Dow
Journal:  Vaccine       Date:  2011-05-19       Impact factor: 3.641

Review 5.  HSV-2: in pursuit of a vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

6.  Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes.

Authors:  David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Tarek Hamouda; Derek A Pullum; Gary Cohen; Vira Bitko; Ali Fattom
Journal:  Vaccine       Date:  2019-09-09       Impact factor: 3.641

7.  Recurrent vaginal shedding of herpes simplex type 2 virus in the mouse and effects of antiviral therapy.

Authors:  Nicholas Farley; David I Bernstein; Fernando J Bravo; Julie Earwood; Nancy Sawtell; Rhonda D Cardin
Journal:  Antiviral Res       Date:  2010-02-16       Impact factor: 5.970

8.  An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.

Authors:  Mojca Skoberne; Rhonda Cardin; Alexander Lee; Ana Kazimirova; Veronica Zielinski; Danielle Garvie; Amy Lundberg; Shane Larson; Fernando J Bravo; David I Bernstein; Jessica B Flechtner; Deborah Long
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

9.  Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.

Authors:  Brent Stanfield; Konstantin Gus Kousoulas
Journal:  Curr Clin Microbiol Rep       Date:  2015-07-01

Review 10.  Alphaherpesvirus Vaccines.

Authors:  Clare Burn Aschner; Betsy C Herold
Journal:  Curr Issues Mol Biol       Date:  2020-09-23       Impact factor: 2.081
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.